MC2 Therapeutics

MC2 Therapeutics is a specialized dermatology company leveraging its proprietary PAD Technology™ formulation platform to create advanced topical treatments for psoriasis and related inflammatory skin conditions. The company has transitioned to a commercial-stage entity with its lead product, Wynzora® Cream, approved in multiple regions including Canada, and is actively expanding through strategic partnerships in key markets like China and Australia. With a pipeline focused on immune-mediated skin diseases and a holistic approach to patient care, MC2 is positioning itself as a leader in next-generation topical drug delivery.

Proprietary PAD Technology™, a formulation and drug delivery system designed to create patient-preferred topical creams with optimized efficacy for immune-mediated and inflammatory skin conditions.

MC2 competes in the crowded psoriasis treatment market against generic topical steroids/vitamin D analogs, other branded topical formulations, and systemic therapies including biologics. Its differentiation is based on formulation advantages (PAD Technology™) aiming for better patient experience and adherence, rather than a novel mechanism of action.